I joined the Oxford Vaccine Group Department of Paediatrics as a senior statistician in 2017 after receiving more than 4 years of training as a Research Fellow (Clinical Trial Statistician) at the Imperial Clinical Trial Unit.
My experiences in trials cover a broad range of therapeutic areas, including cancer, surgery, nutrition and vaccination and ranging from early phase to late phase. My research interest is mainly in developing efficient trial designs and practical implementation of such designs in clinical trials, for example, model based adaptive designs in early phase dose-finding trials evaluating safety and efficacy. I am also interested in applying biomarkers in late phase trial design and benefit and risk assessment.
I am actively involved in postgraduate teaching. I designed a 4-hour training course ‘Introduction to Statistics’ for MSc in Cancer Biology students and was co-leader of the ‘Introduction to Statistics R practical module’ for MSc in Epidemiology students while working at the Imperial College London. I have also been involved in tutoring in a few other courses, such as Bayesian Statistics and Advanced Topics in Biostatistics. I have supervised two MSc students for their summer projects and one NIHR Research Methods Fellow at the Imperial Clinical Trial Unit.
I completed a Preventive Medicine Degree at Peking University in 2005. After that, I was trained in Epidemiology and Biostatistics at Peking University and University of Cambridge and obtained my PhD and MPhil degrees.
Are better existing WASH practices in urban slums associated with a lower long-term risk of severe cholera? A prospective cohort study with 4 years of follow-up in Mirpur, Bangladesh.
Kang S. et al, (2022), BMJ Open, 12
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial.
Li G. et al, (2022), Lancet, 399, 2212 - 2225
Immunogenicity of a single 4CMenB vaccine booster in adolescents 11 years after childhood immunisation.
Rollier CS. et al, (2022), Vaccine
Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.
Shaw RH. et al, (2022), Lancet Respir Med
Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS. et al, (2022), Lancet Infect Dis